Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$80.19 +0.4%	$74.18	$61.24 ▼ $87.25	$247.80B	0.37	3.58 million shs	2.99 million shs
ISRG Intuitive Surgical	$469.07 -0.9%	$498.54	$425.00 ▼ $616.00	$169.67B	1.61	1.74 million shs	2.23 million shs
TMUS T-Mobile US	$255.89 +1.5%	$241.82	$192.61 ▼ $276.49	$283.59B	0.61	3.74 million shs	4.05 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+0.36%	+0.17%	+8.44%	+9.85%	-8.48%
ISRG Intuitive Surgical	-0.89%	-1.09%	-2.91%	-15.93%	-4.78%
TMUS T-Mobile US	+1.55%	+1.87%	+7.88%	+5.76%	+28.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	2.8779 of 5 stars	1.4	5.0	2.5	0.0	3.0	0.0	2.5
ISRG Intuitive Surgical	4.9574 of 5 stars	4.3	3.0	0.0	4.0	3.0	2.5	3.1
TMUS T-Mobile US	4.7529 of 5 stars	2.3	5.0	2.5	3.4	2.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	2.80	Moderate Buy	$86.00	7.25% Upside
ISRG Intuitive Surgical	2.60	Moderate Buy	$595.95	27.05% Upside
TMUS T-Mobile US	2.56	Moderate Buy	$258.02	0.83% Upside

Current Analyst Ratings Breakdown

Latest TMUS, ISRG, and AZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	TMUS T-Mobile US	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$286.00
8/22/2025	ISRG Intuitive Surgical	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell
8/20/2025	ISRG Intuitive Surgical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/19/2025	ISRG Intuitive Surgical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$615.00
7/25/2025	TMUS T-Mobile US	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$265.00 ➝ $270.00
7/24/2025	TMUS T-Mobile US	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$270.00 ➝ $280.00
7/24/2025	TMUS T-Mobile US	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$265.00 ➝ $285.00
7/23/2025	ISRG Intuitive Surgical	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$547.00 ➝ $585.00
7/23/2025	ISRG Intuitive Surgical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$575.00 ➝ $595.00
7/23/2025	ISRG Intuitive Surgical	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$590.00 ➝ $600.00
7/23/2025	ISRG Intuitive Surgical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$559.00 ➝ $599.00

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.60	$6.32 per share	12.69	$14.45 per share	5.55
ISRG Intuitive Surgical	$8.35B	20.13	$7.92 per share	59.25	$50.08 per share	9.37
TMUS T-Mobile US	$81.40B	3.54	$21.58 per share	11.86	$54.30 per share	4.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.66	30.15	16.04	1.47	14.68%	32.84%	12.87%	11/11/2025 (Estimated)
ISRG Intuitive Surgical	$2.32B	$7.17	65.42	61.48	4.96	28.51%	14.56%	12.93%	10/16/2025 (Estimated)
TMUS T-Mobile US	$11.34B	$10.60	24.14	20.82	1.38	14.53%	19.68%	5.78%	10/23/2025 (Estimated)

Latest TMUS, ISRG, and AZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	AZN AstraZeneca	$1.09	$1.09	N/A	$0.79	$14.08 billion	$14.46 billion
7/23/2025	Q2 2025	TMUS T-Mobile US	$2.69	$2.84	+$0.15	$2.84	$20.99 billion	$21.13 billion
7/22/2025	Q2 2025	ISRG Intuitive Surgical	$1.93	$2.19	+$0.26	$1.81	$2.35 billion	$2.44 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$1.01	1.26%	N/A	37.97%	N/A
ISRG Intuitive Surgical	N/A	N/A	N/A	N/A	N/A
TMUS T-Mobile US	$3.52	1.38%	N/A	33.21%	N/A

Latest TMUS, ISRG, and AZN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/5/2025	TMUS T-Mobile US	quarterly	$0.88	1.4%	8/29/2025	8/29/2025	9/11/2025
7/29/2025	AZN AstraZeneca	semi-annual	$0.5050	2%	8/8/2025	8/8/2025	9/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.55	0.86	0.67
ISRG Intuitive Surgical	N/A	5.17	4.18
TMUS T-Mobile US	1.33	1.21	1.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
ISRG Intuitive Surgical	83.64%
TMUS T-Mobile US	42.49%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
ISRG Intuitive Surgical	0.70%
TMUS T-Mobile US	0.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
ISRG Intuitive Surgical	15,638	358.48 million	355.97 million	Optionable
TMUS T-Mobile US	70,000	1.13 billion	1.12 billion	Optionable

TMUS, ISRG, and AZN Headlines

Recent News About These Companies

Here's Why T-Mobile (TMUS) is a Strong Growth Stock

September 2 at 5:31 PM | zacks.com

Point72 Europe London LLP Has $23.62 Million Stake in T-Mobile US, Inc. $TMUS

September 2 at 9:40 AM | marketbeat.com

T-Mobile US, Inc. $TMUS Stake Lowered by Steamboat Capital Partners LLC

September 2 at 8:33 AM | marketbeat.com

T-Mobile US, Inc. $TMUS is Cyrus J. Lawrence LLC's 7th Largest Position

September 2 at 8:11 AM | marketbeat.com

DRW Securities LLC Increases Stake in T-Mobile US, Inc. $TMUS

September 2 at 7:08 AM | marketbeat.com

Baird Financial Group Inc. Raises Position in T-Mobile US, Inc. $TMUS

September 2 at 6:42 AM | marketbeat.com

Panagora Asset Management Inc. Has $28.75 Million Stock Holdings in T-Mobile US, Inc. $TMUS

September 2 at 6:26 AM | marketbeat.com

T-Mobile US, Inc. $TMUS Shares Sold by Jump Financial LLC

September 2 at 4:36 AM | marketbeat.com

Is T-Mobile US Stock Outperforming the S&P 500?

September 1 at 4:25 PM | finance.yahoo.com

T-Mobile US, Inc. $TMUS Shares Sold by The Manufacturers Life Insurance Company

September 1 at 5:44 AM | marketbeat.com

T-Mobile US, Inc. $TMUS Shares Sold by CreativeOne Wealth LLC

September 1 at 4:54 AM | marketbeat.com

T-Mobile US, Inc. $TMUS Shares Bought by Stony Point Capital LLC

August 31 at 7:36 AM | marketbeat.com

Vident Advisory LLC Grows Stock Holdings in T-Mobile US, Inc. $TMUS

August 31 at 7:36 AM | marketbeat.com

T-Mobile US, Inc. $TMUS Shares Bought by Canada Pension Plan Investment Board

August 31 at 7:14 AM | marketbeat.com

OMERS ADMINISTRATION Corp Has $5.05 Million Stock Holdings in T-Mobile US, Inc. $TMUS

August 31 at 5:51 AM | marketbeat.com

Insider Selling: T-Mobile US (NASDAQ:TMUS) Director Sells $17,554,284.00 in Stock

August 31 at 4:17 AM | americanbankingnews.com

T-Mobile: Primed For All-Time Highs

August 30, 2025 | seekingalpha.com

HAP Trading LLC Trims Position in T-Mobile US, Inc. $TMUS

August 30, 2025 | marketbeat.com

Lansforsakringar Fondforvaltning AB publ Has $45.49 Million Stock Position in T-Mobile US, Inc. $TMUS

August 30, 2025 | marketbeat.com

T-Mobile US (NASDAQ:TMUS) Director Sells $17,545,903.20 in Stock

August 30, 2025 | insidertrades.com

B. Metzler seel. Sohn & Co. AG Reduces Stake in T-Mobile US, Inc. $TMUS

August 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TMUS, ISRG, and AZN Company Descriptions

AstraZeneca NASDAQ:AZN

$80.19 +0.29 (+0.36%)

Closing price 09/2/2025 04:00 PM Eastern

Extended Trading

$80.41 +0.22 (+0.27%)

As of 09/2/2025 07:56 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Intuitive Surgical NASDAQ:ISRG

$469.07 -4.23 (-0.89%)

Closing price 09/2/2025 04:00 PM Eastern

Extended Trading

$467.50 -1.57 (-0.33%)

As of 09/2/2025 07:59 PM Eastern

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

T-Mobile US NASDAQ:TMUS

$255.89 +3.90 (+1.55%)

Closing price 09/2/2025 04:00 PM Eastern

Extended Trading

$255.40 -0.49 (-0.19%)

As of 09/2/2025 07:57 PM Eastern

T-Mobile US, Inc., together with its subsidiaries, provides mobile communications services in the United States, Puerto Rico, and the United States Virgin Islands. The company offers voice, messaging, and data services to customers in the postpaid, prepaid, and wholesale and other services. It also provides wireless devices, including smartphones, wearables, tablets, home broadband routers, and other mobile communication devices, as well as wireless devices and accessories; financing through equipment installment plans; reinsurance for device insurance policies and extended warranty contracts; leasing through JUMP! On Demand; and High Speed Internet services. In addition, the company offers services, devices, and accessories under the T-Mobile and Metro by T-Mobile brands through its owned and operated retail stores, T-Mobile app and customer care channels, and its websites. It also sells its devices to dealers and other third-party distributors for resale through independent third-party retail outlets and various third-party websites. The company was founded in 1994 and is headquartered in Bellevue, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time